medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-16-13-18medalphabet-3832Research ArticleСтатьиФитонутриенты в комплексной диетотерапии алкогольной болезни печени и неалкогольной жировой болезни печениPhytonutrients in complex diet therapy for alcoholic liver disease and non-alcoholic fatty liver diseasehttps://orcid.org/0000-0002-4689-3591ОрловаС. В.OrlovaS. V.

Орлова Светлана Владимировна, д. м. н., проф., зав. кафедрой диетологии и клинической нутрициологии, главный научный сотрудник

Москва

Orlova Svetlana V., DM Sci (habil.), professor, head of Dept of Dietetics and Clinical Nutritiology, Chief Researcher

Moscow

orlova-sv@rudn.ruhttps://orcid.org/0000-0002-5203-1082ВодолазкаяА. Н.VodolazkayaA. N.

Водолазкая Ангелина Николаевна, врач-диетолог

Москва

Vodolazkaya Angelina N., dietitian

Moscow

drvodolazkaya@gmail.comhttps://orcid.org/0000-0001-6376-8189ТарасоваО. И.TarasovaO. I.

Тарасова Ольга Ивановна, к. м. н., доцент, директор центра изучения печени им. проф. П. П. Огурцова, доцент кафедры госпитальная терапия с курсами эндокринологии, гематологии и КЛД

Москва

Tarasova Olga I. PhD Med, associate professor, director of the Center for the Study of the Liver named after Prof. P. P. Ogurtsov, Associate Professor of Dept of Hospital Therapy with courses in Endocrinology, Hematology and Clinical Diagnostics

Moscow

tarasova_oi@pfur.ruhttps://orcid.org/0000-0003-3220-0333НикитинаЕ. А.NikitinaE. A.

Никитина Елена Александровна, к. м. н., доцент кафедры диетологии и клинической нутрициологии, научный сотрудник, эксперт методического аккредитационно-симуляционного центра

Москва

Nikitina Elena A., PhD Med, associate professor of Dept of Dietetics and Clinical Nutrition1, research fellow, expert of the Methodological Accreditation and Simulation Center

Moscow

nikitina-ea1@rudn.ruhttps://orcid.org/0000-0002-3811-9459ПрокопенкоЕ. В.ProkopenkoE. V.

Прокопенко Елена Валерьевна, врач-эндокринолог, диетолог, руководитель отдела развития и сопровождения медицинских информационных системи сервисов

Москва

Prokopenko Elena V., endocrinologist, dietitian, Project Manager of Medical Dept

Moscow

elvprokopenko@gmail.comhttps://orcid.org/0000-0002-0548-3414БалашоваН. В.BalashovaN. V.

Балашова Наталья Валерьевна, к. б. н., доцент кафедры диетологии и клинической нутрициологии, доцент кафедры клинической лабораторной диагностики факультета усовершенствования врачей

Москва

Balashova Natalya V., PhD Bio Sci, assistant professor at Dept of Clinical Laboratory Diagnostics of the Faculty of Advanced Training of Doctors3, assistant professor at Dept of Dietetics and Clinical Nutritiology

Moscow

Author ID: 832745

BalashovaN77@mail.ruhttps://orcid.org/0009-0006-1327-1557МиносянИ. С.MinosyanI. S.

Миносян Илона Сергеевна, б/з, б/с, врач-гастроэнтеролог центра изучения печени им. проф. П. П. Огурцова КДЦ, аспирант кафедры госпитальная терапия с курсами эндокринологии, гематологии и КЛД

Москва

Minosyan Ilona S., b/c, b/c, gastroenterologist at the Prof. P. P. Ogurtsov Center for Liver Studies, CDC RUDN University, postgraduate student of Dept of Hospital Therapy with courses in Endocrinology, Hematology and Clinical Diagnostics

Moscow

1142220093@rudn.ruУразовВ. В.UrazovV. V.

Уразов Виктор Васильевич, директор Института восточной медицины

Москва

Urazov Victor V., director of the Institute of Oriental Medicine

Moscow

urazov-vv@rudn.ruФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН); ГБУЗ «Научно-практический центр детской психоневрологии Департамента здравоохранения г. Москвы»РоссияPeoples’ Friendship University of Russia n. a. Patrice Lumumba (RUDN University); Scientific and Practical Center for Pediatric Psychoneurology of the Moscow Department of HealtRussian FederationГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. ВладимирскогоРоссияMoscow Regional Research Clinical Institute named after M. F. VladimirskyRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН)РоссияPeoples’ Friendship University of Russia n. a. Patrice Lumumba (RUDN University)Russian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН); ГБУЗ «Научно-практический центр детской психоневрологии Департамента здравоохранения г. Москвы»; ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииРоссияPeoples’ Friendship University of Russia n. a. Patrice Lumumba (RUDN University); Scientific and Practical Center for Pediatric Psychoneurology of the Moscow Department of Healt; National Medical Research Center for Therapy and Preventive MedicineRussian FederationООО «ИНВИТРО»Россия“INVITRO” Limited Liability CompanyRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН); ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. Владимирского»РоссияPeoples’ Friendship University of Russia n. a. Patrice Lumumba (RUDN University); Moscow Regional Research Clinical Institute named after M. F. VladimirskyRussian Federation202405092024016Диетология и нутрициология1318Copyright © Орлова С.В., Водолазкая А.Н., Тарасова О.И., Никитина Е.А., Прокопенко Е.В., Балашова Н.В., Миносян И.С., Уразов В.В., 20242024Орлова С.В., Водолазкая А.Н., Тарасова О.И., Никитина Е.А., Прокопенко Е.В., Балашова Н.В., Миносян И.С., Уразов В.В.Orlova S.V., Vodolazkaya A.N., Tarasova O.I., Nikitina E.A., Prokopenko E.V., Balashova N.V., Minosyan I.S., Urazov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3832

Серьезную проблему общественного здравоохранения с разными эпидемиологическими профилями представляют собой как алкогольная болезнь печени (АБП), так и неалкогольная жировая болезнь печени (НАЖБП). Долгосрочной целью лечения хронического гепатоза является предотвращение прогрессирования цирроза и/или рака печени и в итоге продление выживаемости и качество жизни пациентов. Большим потенциалом в оптимизации терапевтического воздействия у таких пациентов обладают фитодобавки, содержащие лекарственные растения, такие как расторопша пятнистая, трифала, имбирь и растения рода Филлантус.

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are serious health problems with different epidemiological profiles. The long-term goal of treating chronic hepatosis is to prevent the progression of cirrhosis and/or liver cancer and prolong survival and patient’s quality of life. Herbal supplements containing medicinal plants, such as milk thistle, triphala, ginger and plants of the genus Phyllanthus, have great potential in optimizing the therapeutic effect in such patients.

алкогольная болезнь печени (АБП)неалкогольная жировая болезнь печени (НАЖБП)фитокомплексрасторопша пятнистаятрифалаимбирь и растения рода Филлантусalcoholic liver disease (ALD)non-alcoholic fatty liver disease (NAFLD)phytocomplexMilk ThistleTriphalaGinger and plants of the genus PhyllanthusReferencesJichitu A., Bungau S., Stanescu A. M.A., Vesca C. M., Toma M. M., Bustea C., et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel). 2021; 11 (4): 689. DOI: 10.3390/diagnostics11040689Jichitu A., Bungau S., Stanescu A. M.A., Vesca C. M., Toma M. M., Bustea C., et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel). 2021; 11 (4): 689. DOI: 10.3390/diagnostics11040689Ivashkin V. T., Mayevskaya M. V., Pavlov Ch.S., Tikhonov I. N., Shirokova E. N., Bueverov A. O. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 26 (2): 24–42. (In Russ.). DOI: 10.22416/1382-4376-2016-26-2-24-42Ivashkin V. T., Mayevskaya M. V., Pavlov Ch.S., Tikhonov I. N., Shirokova E. N., Bueverov A. O. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 26 (2): 24–42. (In Russ.). DOI: 10.22416/1382-4376-2016-26-2-24-42Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285.Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285.Maev IV, Abdurakhmanov DT, Andreev DN, Dicheva DT. Alcoholic liver disease: State-of-the-art. Terapevticheskii Arkhiv (Ter. Arkh.). 2014; 86 (4): 108–16.Maev IV, Abdurakhmanov DT, Andreev DN, Dicheva DT. Alcoholic liver disease: State-of-the-art. Terapevticheskii Arkhiv (Ter. Arkh.). 2014; 86 (4): 108–16.Aslam A, Kwo PY. Epidemiology and Disease Burden of Alcohol Associated Liver Disease. J. Clin Exp Hepatol. 2023; 13 (1): 8802. https://doi.org/10.1016/j.jceh.2022.09.001Aslam A, Kwo PY. Epidemiology and Disease Burden of Alcohol Associated Liver Disease. J. Clin Exp Hepatol. 2023; 13 (1): 8802. https://doi.org/10.1016/j.jceh.2022.09.001Manthey J. et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019; 393: 2493–2502. DOI: 10.1016/S 0140-6736(18)32744-2Manthey J. et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet. 2019; 393: 2493–2502. DOI: 10.1016/S 0140-6736(18)32744-2WHO. Alcohol. Available at: https://www.who.int/news-room/fact-sheets/detail/alcoholWHO. Alcohol. Available at: https://www.who.int/news-room/fact-sheets/detail/alcoholRitchie H, Roser M. Alcohol Consumption. Our World in Data Published online at OurWorldInData.org. 2018. Available at: https://ourworldindata.org/alcohol-consumptionRitchie H, Roser M. Alcohol Consumption. Our World in Data Published online at OurWorldInData.org. 2018. Available at: https://ourworldindata.org/alcohol-consumptionZamyatnina E. The structure of directly related alcohol mortality In Russia from 2011 to 2021. Demographic Review. 2022; 9 (2): 102–118. (In Russ.). https://doi.org/10.17323/demreview.v9i2.16208Zamyatnina E. The structure of directly related alcohol mortality In Russia from 2011 to 2021. Demographic Review. 2022; 9 (2): 102–118. (In Russ.). https://doi.org/10.17323/demreview.v9i2.16208Nikonov EL, Aksenov VA. Current approaches to diagnosing and treating nonalcoholic fatty liver disease. Russian Journal of Preventive Medicine. 2018; 21 (3): 62–69. (In Russ.) https://doi.org/10.17116/profmed201831262Nikonov EL, Aksenov VA. Current approaches to diagnosing and treating nonalcoholic fatty liver disease. Russian Journal of Preventive Medicine. 2018; 21 (3): 62–69. (In Russ.) https://doi.org/10.17116/profmed201831262Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012; 91: 319–327.Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012; 91: 319–327.Byrne C. D., Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015; 62 (1S): S 47–S 64. DOI: 10.1016/j.jhep.2014.12.012Byrne C. D., Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015; 62 (1S): S 47–S 64. DOI: 10.1016/j.jhep.2014.12.012Fang Y. L., Chen H., Wang C. L., Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory” to “multiple hit model”. World J. Gastroenterol. 2018; 24: 2974–83. DOI: 10.3748/wjg.v24.i27.2974Fang Y. L., Chen H., Wang C. L., Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory” to “multiple hit model”. World J. Gastroenterol. 2018; 24: 2974–83. DOI: 10.3748/wjg.v24.i27.2974Xian Y. X., Weng J. P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020; 134: 8–19.Xian Y. X., Weng J. P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020; 134: 8–19.Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients. 2020 Sep 10; 12 (9): 2762. DOI: 10.3390/nu12092762Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients. 2020 Sep 10; 12 (9): 2762. DOI: 10.3390/nu12092762Clinical guidelines – Non-alcoholic fatty liver disease in adults – 2022–2023–2024 (11/11/2022). Approved by the Ministry of Health of the Russian Federation. Email resource: https://cr.minzdrav.gov.ru/recomend/711_1 (date of access: 06/26/2024).Clinical guidelines – Non-alcoholic fatty liver disease in adults – 2022–2023–2024 (11/11/2022). Approved by the Ministry of Health of the Russian Federation. Email resource: https://cr.minzdrav.gov.ru/recomend/711_1 (date of access: 06/26/2024).European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78. DOI: 10.1053/j.gastro.2015.04.005Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78. DOI: 10.1053/j.gastro.2015.04.005Tendler D., Lin S., Yancy W. S. Jr, Mavropousol J., Sylvestre P., Rockey D. C. et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007; 52 (2): 589–93. DOI: 10.1007/s10620-006-9433-5Tendler D., Lin S., Yancy W. S. Jr, Mavropousol J., Sylvestre P., Rockey D. C. et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007; 52 (2): 589–93. DOI: 10.1007/s10620-006-9433-5Ryan M. C., Itsiopoulos C., Thodis T., Ward G., Trost N., Hofferberth S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013; 59 (1): 138–43. DOI: 10.1016/j.jhep.2013.02.012Ryan M. C., Itsiopoulos C., Thodis T., Ward G., Trost N., Hofferberth S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013; 59 (1): 138–43. DOI: 10.1016/j.jhep.2013.02.012Saeed N., Nadeau B., Shannon C., Tincopa M. Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review. Nutrients. 2019; 11 (12): 3064. DOI: 10.3390/nu11123064Saeed N., Nadeau B., Shannon C., Tincopa M. Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review. Nutrients. 2019; 11 (12): 3064. DOI: 10.3390/nu11123064Moosavian S. P., Arab A., Paknahad Z. The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Clin Nutr ESPEN. 2020; 35: 40–6. DOI: 10.1016/j.clnesp.2019.10.008Moosavian S. P., Arab A., Paknahad Z. The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Clin Nutr ESPEN. 2020; 35: 40–6. DOI: 10.1016/j.clnesp.2019.10.008Wong V. W., Wong G. L., Chan R. S., Shu S. S.-T., Cheung B. H.-K., Li L. S. et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J. Hepatol. 2018; 69 (6): 1349–56. DOI: 10.1016/j.jhep.2018.08.011Wong V. W., Wong G. L., Chan R. S., Shu S. S.-T., Cheung B. H.-K., Li L. S. et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J. Hepatol. 2018; 69 (6): 1349–56. DOI: 10.1016/j.jhep.2018.08.011Francque S. M., Marchesini G., Kautz A., Walmsley M., Dorner R., Lazarus J. V., et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021; 3 (5): 100322. DOI: 10.1016/j.jhepr.2021.100322Francque S. M., Marchesini G., Kautz A., Walmsley M., Dorner R., Lazarus J. V., et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021; 3 (5): 100322. DOI: 10.1016/j.jhepr.2021.100322Zhao L., Zhang F., Ding X., Wu G., Lam Y. Y., Wang X., et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018; 359 (6380): 1151–6. DOI: 10.1126/science.aao5774Zhao L., Zhang F., Ding X., Wu G., Lam Y. Y., Wang X., et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018; 359 (6380): 1151–6. DOI: 10.1126/science.aao5774Lemstra M., Bird Y., Nwankwo C., Rogers M. Moraros J. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer Adherence. 2016; 10: 1547–59. DOI: 10.2147/PPA. S 103649Lemstra M., Bird Y., Nwankwo C., Rogers M. Moraros J. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer Adherence. 2016; 10: 1547–59. DOI: 10.2147/PPA. S 103649Kaganov B. S., Sharafetdinov Kh. Kh. Therapeutic nutrition for diseases of the hepatobiliary system // Questions of dietology. 2015; 3 (5): 5–12.Kaganov B. S., Sharafetdinov Kh. Kh. Therapeutic nutrition for diseases of the hepatobiliary system // Questions of dietology. 2015; 3 (5): 5–12.Shirokikh A. V., Vyalov S. S. Alcoholic steatosis and chronic alcoholic hepatitis: features of pathogenesis and treatment tactics // Consilium Medicum. Gastroenterology. (App.) 2013; (1): 21–27.Shirokikh A. V., Vyalov S. S. Alcoholic steatosis and chronic alcoholic hepatitis: features of pathogenesis and treatment tactics // Consilium Medicum. Gastroenterology. (App.) 2013; (1): 21–27.Ivashkin V. T., Mayevskaya M. V., Zharkova M. S. et al. Algorithms for diagnosis and treatment in hepatology: Reference materials. M.: MEDpress-inform, 2016. Pp. 43–54.Ivashkin V. T., Mayevskaya M. V., Zharkova M. S. et al. Algorithms for diagnosis and treatment in hepatology: Reference materials. M.: MEDpress-inform, 2016. Pp. 43–54.Mathurin P., O’Grady J., Carithers R. L. et al. Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data // Gut. 2011; 60: 255–260.Mathurin P., O’Grady J., Carithers R. L. et al. Corticosteroids improve shortterm survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data // Gut. 2011; 60: 255–260.Yao J., Zhi M., Gao X., Hu P., Li C., Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz. J. Med. Biol. Res. 2013; 46: 270–277. DOI: 10.1590/1414–431X20122551Yao J., Zhi M., Gao X., Hu P., Li C., Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz. J. Med. Biol. Res. 2013; 46: 270–277. DOI: 10.1590/1414–431X20122551Li H. B., Yang Y. R., Mo Z. J., Ding Y., Jiang W. J. Silibinin improves palmitate-induced insulin resistance in C 2C 12 myotubes by attenuating IRS‑1/PI3K/Akt pathway inhibition. Braz. J. Med. Biol. Res. 2015; 48: 440–446. DOI: 10.1590/1414-431X20144238Li H. B., Yang Y. R., Mo Z. J., Ding Y., Jiang W. J. Silibinin improves palmitate-induced insulin resistance in C 2C 12 myotubes by attenuating IRS‑1/PI3K/Akt pathway inhibition. Braz. J. Med. Biol. Res. 2015; 48: 440–446. DOI: 10.1590/1414-431X20144238Federico A., Trappoliere M., Tuccillo C., de Sio I., Di Leva A., Del Vecchio Blanco C., Loguercio C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: Preliminary observations. Gut. 2006; 55: 901–902. DOI: 10.1136/gut.2006.091967Federico A., Trappoliere M., Tuccillo C., de Sio I., Di Leva A., Del Vecchio Blanco C., Loguercio C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: Preliminary observations. Gut. 2006; 55: 901–902. DOI: 10.1136/gut.2006.091967Pferschy-Wenzig E.M., Atanasov A. G., Malainer C., Noha S. M., Kunert O., Schuster D., Heiss E. H., Oberlies N. H., Wagner H., Bauer R. et al. Identification of Isosilybin A from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J. Nat. Prod. 2014; 77: 842–847. DOI: 10.1021/np400943bPferschy-Wenzig E.M., Atanasov A. G., Malainer C., Noha S. M., Kunert O., Schuster D., Heiss E. H., Oberlies N. H., Wagner H., Bauer R. et al. Identification of Isosilybin A from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J. Nat. Prod. 2014; 77: 842–847. DOI: 10.1021/np400943bIvashkin V. T., Mayevskaya M. V. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. Rus. J. Gastroenterol Hepatol Coloproctol. 2022; 32 (4). doi.org/10.22416/1382-4376-2022-32-4-104-140Ivashkin V. T., Mayevskaya M. V. et al. Clinical guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. Rus. J. Gastroenterol Hepatol Coloproctol. 2022; 32 (4). doi.org/10.22416/1382-4376-2022-32-4-104-140Nehmi-Filho V, Santamarina AB, de Freitas JA, Trarbach EB, de Oliveira DR, Palace-Berl F, de Souza E, de Miranda DA, Escamilla-Garcia A, Otoch JP, Pessoa AFM. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: A double-blind randomized trial. Front Endocrinol (Lausanne). 2023 Jan 27; 13: 1089938. DOI: 10.3389/fendo.2022.1089938. PMID: 36778595; PMCID: PMC 9912840Nehmi-Filho V, Santamarina AB, de Freitas JA, Trarbach EB, de Oliveira DR, Palace-Berl F, de Souza E, de Miranda DA, Escamilla-Garcia A, Otoch JP, Pessoa AFM. Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and Silybum marianum (silymarin) ameliorate obesity-related metabolic and clinical parameters: A double-blind randomized trial. Front Endocrinol (Lausanne). 2023 Jan 27; 13: 1089938. DOI: 10.3389/fendo.2022.1089938. PMID: 36778595; PMCID: PMC 9912840Navarro VJ, Belle SH, D’Amato M, Adfhal N, Brunt EM, Fried MW, Reddy KR, Wahed AS, Harrison S; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One. 2019 Sep 19; 14 (9): e0221683. DOI: 10.1371/journal.pone.0221683Navarro VJ, Belle SH, D’Amato M, Adfhal N, Brunt EM, Fried MW, Reddy KR, Wahed AS, Harrison S; Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial. PLoS One. 2019 Sep 19; 14 (9): e0221683. DOI: 10.1371/journal.pone.0221683Pulok K. Mukherjee et all. Clinical Study of ‘Triphala’ – A Well Known Phytomedicine from India, IRANIAN JOURNAL OF PHARMACOLOGY & THERAPEUTICS. 2006; 5: 51–54.Pulok K. Mukherjee et all. Clinical Study of ‘Triphala’ – A Well Known Phytomedicine from India, IRANIAN JOURNAL OF PHARMACOLOGY & THERAPEUTICS. 2006; 5: 51–54.Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014; 20 (42): 15518–31. DOI: 10.3748/wjg.v20. i42.15518Paolella G., Mandato C., Pierri L., Poeta M., Di Stasi M., Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014; 20 (42): 15518–31. DOI: 10.3748/wjg.v20. i42.15518Plotnikova E. Yu., Gracheva T. Yu., Yerzhanova E. A. The role of intestinal microflora in the formation of non-alcoholic fatty liver disease. The Attending Physician. 2017; 2: 32–8.Plotnikova E. Yu., Gracheva T. Yu., Yerzhanova E. A. The role of intestinal microflora in the formation of non-alcoholic fatty liver disease. The Attending Physician. 2017; 2: 32–8.Zorn A. M., Wells J. M. Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol. 2009; 25: 221–51. DOI: 10.1146/annurev.cellbio.042308.113344Zorn A. M., Wells J. M. Vertebrate endoderm development and organ formation. Annu Rev Cell Dev Biol. 2009; 25: 221–51. DOI: 10.1146/annurev.cellbio.042308.113344Carlsen MH, Halvorsen BL, Holte K, Bøhn SK, Dragland S, Sampson L, Willey C, Senoo H, Umezono Y, Sanada C, Barikmo I, Berhe N, Willett WC, Phillips KM, Jacobs DR Jr, Blomhoff R. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J. 2010 Jan 22; 9: 3. DOI: 10.1186/1475-2891-9-3Carlsen MH, Halvorsen BL, Holte K, Bøhn SK, Dragland S, Sampson L, Willey C, Senoo H, Umezono Y, Sanada C, Barikmo I, Berhe N, Willett WC, Phillips KM, Jacobs DR Jr, Blomhoff R. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutr J. 2010 Jan 22; 9: 3. DOI: 10.1186/1475-2891-9-3Yadav S, Gite S, Nilegaonkar S, Agte V. Effect of supplementation of micronutrients and phytochemicals to fructooligosaccharides on growth response of probiotics and E. coli. Biofactors. 2011 Jan-Feb; 37 (1): 58–64. DOI: 10.1002/biof.137Yadav S, Gite S, Nilegaonkar S, Agte V. Effect of supplementation of micronutrients and phytochemicals to fructooligosaccharides on growth response of probiotics and E. coli. Biofactors. 2011 Jan-Feb; 37 (1): 58–64. DOI: 10.1002/biof.137Tabasco R, Sánchez-Patán F, Monagas M, Bartolomé B, Victoria Moreno-Arribas M, Peláez C, Requena T. Effect of grape polyphenols on lactic acid bacteria and bifidobacteria growth: resistance and metabolism. Food Microbiol. 2011 Oct; 28 (7): 1345–52. DOI: 10.1016/j.fm.2011.06.005Tabasco R, Sánchez-Patán F, Monagas M, Bartolomé B, Victoria Moreno-Arribas M, Peláez C, Requena T. Effect of grape polyphenols on lactic acid bacteria and bifidobacteria growth: resistance and metabolism. Food Microbiol. 2011 Oct; 28 (7): 1345–52. DOI: 10.1016/j.fm.2011.06.005Olennikov DN, Kashchenko NI, Chirikova NK. In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepaten® Formulation. Nutrients. 2015 Oct 13; 7 (10): 8456–77. DOI: 10.3390/nu7105406Olennikov DN, Kashchenko NI, Chirikova NK. In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepaten® Formulation. Nutrients. 2015 Oct 13; 7 (10): 8456–77. DOI: 10.3390/nu7105406Jagetia GC, Malagi KJ, Baliga MS, Venkatesh P, Veruva RR. Triphala, an ayurvedic rasayana drug, protects mice against radiation-induced lethality by free-radical scavenging. J. Altern Complement Med. 2004 Dec; 10 (6): 971–8. DOI: 10.1089/acm.2004.10.971Jagetia GC, Malagi KJ, Baliga MS, Venkatesh P, Veruva RR. Triphala, an ayurvedic rasayana drug, protects mice against radiation-induced lethality by free-radical scavenging. J. Altern Complement Med. 2004 Dec; 10 (6): 971–8. DOI: 10.1089/acm.2004.10.971Rasool M, Sabina EP. Antiinflammatory effect of the Indian Ayurvedic herbal formulation Triphala on adjuvant-induced arthritis in mice. Phytother Res. 2007 Sep; 21 (9): 889–94. DOI: 10.1002/ptr.2183Rasool M, Sabina EP. Antiinflammatory effect of the Indian Ayurvedic herbal formulation Triphala on adjuvant-induced arthritis in mice. Phytother Res. 2007 Sep; 21 (9): 889–94. DOI: 10.1002/ptr.2183Kalaiselvan S, Rasool M. Triphala exhibits anti-arthritic effect by ameliorating bone and cartilage degradation in adjuvant-induced arthritic rats. Immunol Invest. 2015; 44 (4): 411–26. DOI: 10.3109/08820139.2015.1017047Kalaiselvan S, Rasool M. Triphala exhibits anti-arthritic effect by ameliorating bone and cartilage degradation in adjuvant-induced arthritic rats. Immunol Invest. 2015; 44 (4): 411–26. DOI: 10.3109/08820139.2015.1017047Kalaiselvan S, Rasool MK. Triphala herbal extract suppresses inflammatory responses in LPS-stimulated RAW 264.7 macrophages and adjuvant-induced arthritic rats via inhibition of NF-κB pathway. J. Immunotoxicol. 2016 Jul; 13 (4): 509–25. DOI: 10.3109/1547691X.2015.1136010Kalaiselvan S, Rasool MK. Triphala herbal extract suppresses inflammatory responses in LPS-stimulated RAW 264.7 macrophages and adjuvant-induced arthritic rats via inhibition of NF-κB pathway. J. Immunotoxicol. 2016 Jul; 13 (4): 509–25. DOI: 10.3109/1547691X.2015.1136010Reddy DB, Reddy TC, Jyotsna G, Sharan S, Priya N, Lakshmipathi V, Reddanna P. Chebulagic acid, a COX–LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO‑205 cell line. J. Ethnopharmacol. 2009 Jul 30;124 (3): 506–12. DOI: 10.1016/j.jep.2009.05.022Reddy DB, Reddy TC, Jyotsna G, Sharan S, Priya N, Lakshmipathi V, Reddanna P. Chebulagic acid, a COX–LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO‑205 cell line. J. Ethnopharmacol. 2009 Jul 30;124 (3): 506–12. DOI: 10.1016/j.jep.2009.05.022Phetkate P, Kummalue T, Rinthong PO, Kietinun S, Sriyakul K. Study of the safety of oral Triphala aqueous extract on healthy volunteers. J. Integr Med. 2020 Jan; 18 (1): 35–40. DOI: 10.1016/j.joim.2019.10.002Phetkate P, Kummalue T, Rinthong PO, Kietinun S, Sriyakul K. Study of the safety of oral Triphala aqueous extract on healthy volunteers. J. Integr Med. 2020 Jan; 18 (1): 35–40. DOI: 10.1016/j.joim.2019.10.002Londhe J. S., Devasagayam T. P.A., Foo, L.Y., Ghaskadbi S. S. (2008). Antioxidant activity of some polyphenol constituents of the medicinal plant Phyllanthus amarus Linn. Redox Report. 13(5): 199–207. https://doi.org/10.1179/135100008X308984Londhe J. S., Devasagayam T. P.A., Foo, L.Y., Ghaskadbi S. S. (2008). Antioxidant activity of some polyphenol constituents of the medicinal plant Phyllanthus amarus Linn. Redox Report. 13(5): 199–207. https://doi.org/10.1179/135100008X308984Kahkeshani N, Farzaei F, Fotouhi M, Alavi SS, Bahramsoltani R, Naseri R, Momtaz S, Abbasabadi Z, Rahimi R, Farzaei MH, Bishayee A. Pharmacological effects of gallic acid in health and diseases: A mechanistic review. Iran J. Basic Med Sci. 2019 Mar; 22 (3): 225–237. DOI: 10.22038/ijbms.2019.32806.7897Kahkeshani N, Farzaei F, Fotouhi M, Alavi SS, Bahramsoltani R, Naseri R, Momtaz S, Abbasabadi Z, Rahimi R, Farzaei MH, Bishayee A. Pharmacological effects of gallic acid in health and diseases: A mechanistic review. Iran J. Basic Med Sci. 2019 Mar; 22 (3): 225–237. DOI: 10.22038/ijbms.2019.32806.7897Punithavathi VR., Stanely Mainzen Prince P., Kumar MR., Selvakumari CJ. Protective effects of gallic acid on hepatic lipid peroxide metabolism, glycoprotein components and lipids in streptozotocin-induced type II diabetic wistar rats. J. Biochem Mol. Toxicol. 2011; 25 (2): 68–76.Punithavathi VR., Stanely Mainzen Prince P., Kumar MR., Selvakumari CJ. Protective effects of gallic acid on hepatic lipid peroxide metabolism, glycoprotein components and lipids in streptozotocin-induced type II diabetic wistar rats. J. Biochem Mol. Toxicol. 2011; 25 (2): 68–76.Ferk F., Kundi, M., Brath, H et al. Gallic acid improves Health-associated biochemical parameters and prevents oxidative damage of DNA in type 2 diabetes patients: results of a placebo-controlled pilot study. Mol Nutr Food Res. 2018; 62 (4): 1700482.Ferk F., Kundi, M., Brath, H et al. Gallic acid improves Health-associated biochemical parameters and prevents oxidative damage of DNA in type 2 diabetes patients: results of a placebo-controlled pilot study. Mol Nutr Food Res. 2018; 62 (4): 1700482.Hsu CL., Yen GC. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br. J. Nutr. 2007; 98 (4): 727–735.Hsu CL., Yen GC. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br. J. Nutr. 2007; 98 (4): 727–735.Choubey S, Varughese L, Kumar V, Beniwal V. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm Pat Anal. 2015; 4: 305–315.Choubey S, Varughese L, Kumar V, Beniwal V. Medicinal importance of gallic acid and its ester derivatives: a patent review. Pharm Pat Anal. 2015; 4: 305–315.Bilalova A. R., Makashova V. V. Clinical and laboratory characteristics of chronic hepatitis and various cirrhosis of the liver. The Russian Archives of Internal Medicine. 2015; (2): 8–14. (In Russ.). https://doi.org/10.20514/2226–6704–2015–0–2–8–14Bilalova A. R., Makashova V. V. Clinical and laboratory characteristics of chronic hepatitis and various cirrhosis of the liver. The Russian Archives of Internal Medicine. 2015; (2): 8–14. (In Russ.). https://doi.org/10.20514/2226–6704–2015–0–2–8–14Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015; 41 (6): 497–520. https://doi.org/10.1111/apt.13090Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015; 41 (6): 497–520. https://doi.org/10.1111/apt.13090Thyagarajan SP, Subramanian S, Thirunaksundari T, Venkateswaran PS, Blumberg BS: Effects of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet. 1988; 2: 764–766.Thyagarajan SP, Subramanian S, Thirunaksundari T, Venkateswaran PS, Blumberg BS: Effects of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet. 1988; 2: 764–766.Thyagrajan SP, Jayaram S, Valliammae T, Madangopalan N, Pal VG, Jayaraman K: Phyllanthus amarus and hepatitis B. Lancet. 1990; 336: 949–950.Thyagrajan SP, Jayaram S, Valliammae T, Madangopalan N, Pal VG, Jayaraman K: Phyllanthus amarus and hepatitis B. Lancet. 1990; 336: 949–950.Thyagarajan SP, Jayaram S, Panneeselvam A. et al.: Effect of Phyllanthus amarus, an Indian medicinal plant on healthy carriers of hepatitis B virus. Results of six clinical trials. Indian J. Gastroenterol. 1999; 18 (Suppl 1): S 26.Thyagarajan SP, Jayaram S, Panneeselvam A. et al.: Effect of Phyllanthus amarus, an Indian medicinal plant on healthy carriers of hepatitis B virus. Results of six clinical trials. Indian J. Gastroenterol. 1999; 18 (Suppl 1): S 26.Thyagrajan SP, Jayaram S, Gopalakrishnan V, Han R, Jayakumar P, Sripathi MS: Herbal medicines for liver diseases in India. J. Gastroenterol Hepatol. 2002; 17: S 370–S 376.Thyagrajan SP, Jayaram S, Gopalakrishnan V, Han R, Jayakumar P, Sripathi MS: Herbal medicines for liver diseases in India. J. Gastroenterol Hepatol. 2002; 17: S 370–S 376.Liu J, Lin H, McIntosh H: Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J. Viral. Hepat. 2001;8: 358–366.Liu J, Lin H, McIntosh H: Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J. Viral. Hepat. 2001;8: 358–366.Yadav NP, Pal A, Shanker K, Bawankule DU, Gupta AK, Darokar MP, S Khanuja SP. Synergistic effect of silymarin and standardized extract of Phyllanthus amarus against CCl4-induced hepatotoxicity in Rattus norvegicus. Phytomedicine. 2008 Dec; 15 (12): 1053–61. DOI: 10.1016/j.phymed.2008.08.002Yadav NP, Pal A, Shanker K, Bawankule DU, Gupta AK, Darokar MP, S Khanuja SP. Synergistic effect of silymarin and standardized extract of Phyllanthus amarus against CCl4-induced hepatotoxicity in Rattus norvegicus. Phytomedicine. 2008 Dec; 15 (12): 1053–61. DOI: 10.1016/j.phymed.2008.08.002Raghavendra Haniadka, Elroy Saldanha, Venkatesh Sunita et al. A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe) Food Funct. 2013; 4: 845–855 $. DOI: 10.1039/c3fo30337cRaghavendra Haniadka, Elroy Saldanha, Venkatesh Sunita et al. A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe) Food Funct. 2013; 4: 845–855 $. DOI: 10.1039/c3fo30337cVasala P. A. Ginger, in Handbook of Herbs and Spices / ed. K. V. Peter. 2004; 1.Vasala P. A. Ginger, in Handbook of Herbs and Spices / ed. K. V. Peter. 2004; 1.Govindarajan V. S. Ginger – chemistry, technology, and quality evaluation: part 1. Crit. Rev. Food Sci. Nutr. 1982; 17: 1–96.Govindarajan V. S. Ginger – chemistry, technology, and quality evaluation: part 1. Crit. Rev. Food Sci. Nutr. 1982; 17: 1–96.Govindarajan V. S. Ginger – chemistry, technology, and quality evaluation: part 2, Crit. Rev. Food Sci. Nutr. 1982; 17: 189–258.Govindarajan V. S. Ginger – chemistry, technology, and quality evaluation: part 2, Crit. Rev. Food Sci. Nutr. 1982; 17: 189–258.Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, Li HB. Bioactive Compounds and Bioactivities of Ginger (Zingiber officinale Roscoe). Foods. 2019 May30; 8 (6): 185. DOI: 10.3390/foods8060185Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, Li HB. Bioactive Compounds and Bioactivities of Ginger (Zingiber officinale Roscoe). Foods. 2019 May30; 8 (6): 185. DOI: 10.3390/foods8060185Suk S., Kwon, G.T., Yang, S. et al. Gingerenone A, a polyphenol present in ginger, suppresses obesity and adipose tissue inflammation in high-fat diet-fed mice. Mol. Nutr. Food Res. 2017; 61: 1700139.Suk S., Kwon, G.T., Yang, S. et al. Gingerenone A, a polyphenol present in ginger, suppresses obesity and adipose tissue inflammation in high-fat diet-fed mice. Mol. Nutr. Food Res. 2017; 61: 1700139.Srivastava K. C. Effects of aqueous extracts of onion, garlic and ginger on platelet aggregation and metabolism of arachidonic acid in the blood vascular system: in vitro study, Prostaglandins, Leukotrienes Med. 1984; 13: 227–235.Srivastava K. C. Effects of aqueous extracts of onion, garlic and ginger on platelet aggregation and metabolism of arachidonic acid in the blood vascular system: in vitro study, Prostaglandins, Leukotrienes Med. 1984; 13: 227–235.Grzanna R., Lindmark L., Frondoza C. G. Ginger – an herbal medicinal product with broad anti- inflammatory actions, J. Med. Food, 2005; 8: 125–132.Grzanna R., Lindmark L., Frondoza C. G. Ginger – an herbal medicinal product with broad anti- inflammatory actions, J. Med. Food, 2005; 8: 125–132.Nirmala K., Prasanna Krishna T., Polasa K. Modulation of xenobiotic metabolism in ginger (Zingiber officinale Roscoe) fed rats. Int. J. Nutr. Metab. 2010; 2: 56–62.Nirmala K., Prasanna Krishna T., Polasa K. Modulation of xenobiotic metabolism in ginger (Zingiber officinale Roscoe) fed rats. Int. J. Nutr. Metab. 2010; 2: 56–62.

The authors declare that there are no conflicts of interest present.